Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

BTAI
BioXcel Therapeutics, Inc. Common Stock
stock NASDAQ

At Close
Jun 10, 2025 3:59:58 PM EDT
1.99USD+1.531%(+0.03)263,119
1.97Bid   2.01Ask   0.04Spread
Pre-market
Jun 10, 2025 9:25:30 AM EDT
1.98USD+1.020%(+0.02)10,054
After-hours
Jun 9, 2025 4:00:30 PM EDT
1.96USD+0.771%(+0.02)0
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 19, 2022
07:00AM EST  BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment of Matt Wiley as Senior Vice President and Chief Commercial Officer (CCO).   GlobeNewswire Inc
Jan 4, 2022
07:00AM EST  BioXcel Therapeutics to Present at the 40th AnnualJ.P.   GlobeNewswire Inc
Dec 15, 2021
07:05AM EST  BioXcel Therapeutics Initiates Pivotal Phase 3 Program Of BXCL501 For Acute Treatment Of Agitation In Patients With Alzheimer's Disease   Benzinga
07:00AM EST  Two Phase 3 studies to enroll a total of 300 patients in assisted living or residential facilities and nursing homes to evaluate the safety and efficacy of BXCL501   GlobeNewswire Inc
Dec 7, 2021
07:31AM EST  BTAI: PDUFA Date for BXCL501 Extended to April 5, 2022   Benzinga
Dec 5, 2021
04:11AM EST  BTAI: Preparations Underway for Commercial Launch of BXCL501; PDUFA Date of Jan. 5, 2022   Benzinga
Dec 1, 2021
08:41AM EST  The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case   Benzinga
08:36AM EST  The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment, Regulatory Setbacks For CTI Biopharma, Favorable Ruling For BioXcel, Viatris In Tecfidera Patent Case   Benzinga
08:03AM EST  Why BioXcel Therapeutics Stock Falling In Pre-market?   RTTNews
07:37AM EST  BioXcel Therapeutics Extends FDA Review Period Of NDA For BXCL501 By Three Months To April 5, 2022   RTTNews
07:27AM EST  BioXcel Therapeutics Announces Extension Of FDA Review Period Of Its NDA For BXCL501 For Acute Treatment Of Agitation Associated With Schizophrenia And Bipolar Disorders To Apr. 5   Benzinga
07:00AM EST  BioXcel Therapeutics Announces Extension of FDA Review Period of   GlobeNewswire Inc
Nov 15, 2021
02:30PM EST  Mid-Afternoon Market Update: Telos Falls After Q3 Results; Creative Realities Shares Spike Higher   Benzinga
12:12PM EST  Mid-Day Market Update: Nasdaq Turns Lower; Casper Sleep Shares Jump   Benzinga
11:21AM EST  Mid-Morning Market Update: Markets Open Higher; Tyson Foods Posts Upbeat Q4 Results   Benzinga
11:20AM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 15, 2021   Benzinga
10:52AM EST  10 Biggest Price Target Changes For Monday   Benzinga
10:46AM EST  Goldman Sachs Downgrades BioXcel Therapeutics to Sell, Lowers Price Target to $24   Benzinga
Nov 11, 2021
07:00AM EST  BioXcel Therapeutics to Present at the 2021 Jefferies London   GlobeNewswire Inc
Nov 10, 2021
08:23AM EST  The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance   Benzinga
07:14AM EST  BioXcel Therapeutics Q3 EPS $(0.96) Beats $(1.05) Estimate   Benzinga
07:00AM EST  Plans for commercial and launch readiness advancing for BXCL501 orally dissolving film, for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II, ahead of January 5, 2022 PDUFA date   GlobeNewswire Inc
04:09AM EST  Earnings Scheduled For November 10, 2021   Benzinga
Oct 27, 2021
07:00AM EDT  BioXcel Therapeutics to Report Third Quarter 2021 Financial   GlobeNewswire Inc
Oct 18, 2021
07:04AM EDT  BioXcel Therapeutics Announces Expansion of Phase 2 Trial of BXCL701 in De Novo and Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer   Benzinga
07:00AM EDT  Initial findings from Phase 1b/2 trial of BXCL701 in combination with KEYTRUDA met efficacy threshold to support expansion of existing cohort of de novo and treatment-emergent Small-Cell Neuroendocrine Prostate Cancer (SCNC)   GlobeNewswire Inc
Sep 23, 2021
07:00AM EDT  Management to showcase AI platform to develop potential treatments for neuropsychiatric disorders   GlobeNewswire Inc
Sep 15, 2021
06:06PM EDT  BXCL701 plus KEYTRUDA (pembrolizumab) demonstrates encouraging anti-tumor activity in heavily pre-treated mCRPC patients with adenocarcinoma   GlobeNewswire Inc
07:38AM EDT  The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs   Benzinga
Sep 12, 2021
06:05PM EDT  BioXcel Therapeutics to Present Updates from Ongoing Trial of   GlobeNewswire Inc
Sep 9, 2021
07:00AM EDT  Live webcast, Revolutionizing Drug Discovery and Development Through AI, to be held from 12:00 PM ET 2:00 PM ET   GlobeNewswire Inc
Sep 3, 2021
11:42AM EDT  BTAI: PDUFA Date of Jan. 5, 2022 for BXCL501   Benzinga
Sep 2, 2021
07:33AM EDT  MindMed, BioXcel Report Publishing Of Int'l. Patent Application Describing System For Identifying Agitation Episodes   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 10, 2021
08:12AM EDT  Clinical-stage biopharmaceutical company BioXcel Therapeutics Inc. (BTAI) on Tuesday reported wider loss in the second quarter, hit by higher compensation costs. The loss was more than what the analysts had predicted.   RTTNews
07:55AM EDT  The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts   Benzinga
07:30AM EDT  BioXcel Therapeutics Q2 Net Loss Of $27.6 Mln Vs Loss Of $21.4 Mln Last Year   RTTNews
07:23AM EDT  BioXcel Therapeutics Q2 EPS $(1.11) Misses $(1.08) Estimate   Benzinga
07:00AM EDT  Phase 3 study of BXCL501 for the acute treatment of agitation associated with dementia expected to begin in Q4 2021   GlobeNewswire Inc
04:05AM EDT  Earnings Scheduled For August 10, 2021   Benzinga
Aug 9, 2021
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
07:00AM EDT  BioXcel Therapeutics to Report Second Quarter 2021 Financial   GlobeNewswire Inc
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 23, 2021
07:45AM EDT  The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs   Benzinga
Jul 19, 2021
07:30AM EDT  BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and Chief Executive Officer of BioXcel, will participate in the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021 at 9:30 a.m. Eastern Time.   GlobeNewswire Inc
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 14, 2021
07:48AM EDT  The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues   Benzinga
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
Jul 7, 2021
07:41AM EDT  The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend   Benzinga
Jun 28, 2021
01:17PM EDT  Analyst Ratings For BioXcel Therapeutics   Benzinga
06:13AM EDT  HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $140   Benzinga
Jun 23, 2021
03:12PM EDT  Shares of clinical-stage biopharmaceutical company BioXcel Therapeutics, Inc. (BTAI) are down 13 percent on Wednesday's trading as the company announced the pricing of an underwritten public offering of 3.15 million shares at $31.70 per share.   RTTNews
08:30AM EDT  BioXcel Therapeutics Prices 3,155,000 Share Common Stock Offering At $31.70/Share   Benzinga
08:29AM EDT  BioXcel Therapeutics Announces Pricing of Public Offering of   GlobeNewswire Inc
07:40AM EDT  Truist Securities Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $125   Benzinga
07:35AM EDT  The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway   Benzinga
06:25AM EDT  A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of PMI Data, Fed Speakers   Benzinga
Jun 22, 2021
04:17PM EDT  BioXcel Therapeutics Earlier Reported $100M Common Stock Offering   Benzinga
04:01PM EDT  BioXcel Therapeutics Announces Proposed Public Offering of Common   GlobeNewswire Inc
Jun 18, 2021
07:00AM EDT  BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that the Company will host a virtual Commercial Day on Friday, June 25, 2021, from 12:00 PM ET 1:30 PM ET.   GlobeNewswire Inc
Jun 1, 2021
11:03AM EDT  Analyst Ratings for BioXcel Therapeutics   Benzinga
06:46AM EDT  HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Raises Price Target to $176   Benzinga
May 26, 2021
07:00AM EDT  BioXcel Therapeutics to Participate in Three Upcoming Healthcare   GlobeNewswire Inc
May 19, 2021
08:11AM EDT  BioXcel's Formulated Dexmedetomidine US Application For Agitation Under FDA Review   Benzinga
07:30AM EDT  The Daily Biotech Pulse: Iovance To Delay Regulatory Filing For Cancer Therapy, Departures At Passage Bio, Positive Readout For Silence Therapeutics   Benzinga
07:27AM EDT  BioXcel: FDA Accepts BXCL501 NDA Filing For Acute Treatment Of Agitation Associated With Schizophrenia& Bipolar Disorder   RTTNews
07:03AM EDT  BioXcel Therapeutics Announces FDA Acceptance For Filing Of NDA For BXCL501 For Acute Treatment Of Agitation Associated With Schizophrenia And Bipolar Disorders I And II   Benzinga
07:00AM EDT  BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA   GlobeNewswire Inc
May 17, 2021
08:21AM EDT  BTAI: Submitting MAA for BXCL501 in Schizophrenia and Bipolar Disorder in 2H21   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 11, 2021
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
07:49AM EDT  10 Biggest Price Target Changes For Tuesday   Benzinga
07:00AM EDT  BioXcel Therapeutics Announces Presentations at the ISBD 2021   GlobeNewswire Inc
06:35AM EDT  HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $170   Benzinga
May 10, 2021
05:18PM EDT  BioXcel Therapeutics Enters Into An Open Market Sales Agreement With Jefferies To Sell Up To $100M Of Its Common Stock   Benzinga
07:16AM EDT  BioXcel Therapeutics Q1 EPS $(1.08) Misses $(0.94) Estimate   Benzinga
07:00AM EDT  Granted FDA Breakthrough Therapy designation for BXCL501 for the acute treatment of agitation associated with dementia; registrational program expected to begin in 2H 2021   GlobeNewswire Inc
04:09AM EDT  Earnings Scheduled For May 10, 2021   Benzinga
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 6, 2021
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
May 5, 2021
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
May 4, 2021
07:00AM EDT  BioXcel Therapeutics to Participate in Two Upcoming Healthcare   GlobeNewswire Inc
May 3, 2021
07:00AM EDT  BioXcel Therapeutics to Host First Quarter 2021 Operating and   GlobeNewswire Inc
Apr 29, 2021
07:00AM EDT  The Campaign, launching during Mental Health Awareness Month, aims to educate healthcare providers on the various signs, symptoms, and levels of severity associated with agitation   GlobeNewswire Inc
Apr 26, 2021
07:00AM EDT  BioXcel Therapeutics Announces Presentations on SERENITY I & II at   GlobeNewswire Inc
Apr 9, 2021
10:11AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 9, 2021   Benzinga
07:55AM EDT  Berenberg Initiates Coverage On BioXcel Therapeutics with Buy Rating, Announces Price Target of $75   Benzinga
Apr 1, 2021
02:37PM EDT  Mid-Afternoon Market Update: Nasdaq Jumps Over 200 Points; AzurRx BioPharma Shares Slide   Benzinga
12:34PM EDT  Truist Securities Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $127   Benzinga
12:04PM EDT  Mid-Day Market Update: Crude Oil Rises Over 1%; BioXcel Therapeutics Shares Plummet   Benzinga
10:14AM EDT  Mid-Morning Market Update: Markets Open Higher; CarMax Profit Beats Views   Benzinga
09:40AM EDT  Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $95   Benzinga
08:42AM EDT  10 Biggest Price Target Changes For Thursday   Benzinga
07:46AM EDT  The Daily Biotech Pulse: Pfizer-BioNTech Preps For BLA Filing, Sonoma Surges, BioXcel Readout, Ortho Clinical Lands Contract   Benzinga
06:42AM EDT  HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $175   Benzinga
06:26AM EDT  BioXcel Stock Is Trading Lower After BXCL501 Data In Opioid Withdrawal Study   Benzinga
Mar 31, 2021
04:02PM EDT  BioXcel Therapeutics Announces Results Of Phase 1b/2 Study Of BXCL501 For The Treatment Of Opioid Withdrawal Symptoms; Co. Reports 'Primary safety endpoint achieved in first study of BXCL501 dosed twice-daily over seven days'   Benzinga
04:01PM EDT  Primary safety endpoint achieved in first study of BXCL501 dosed twice-daily over seven days   GlobeNewswire Inc
Mar 27, 2021
01:01PM EDT  The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week   Benzinga
Mar 15, 2021
09:06AM EDT  FDA Gives Accelerated Review Tag To BioXcel's BXCL501 In Dementia-Related Agitation   Benzinga
07:13AM EDT  BioXcel's BXCL501 Gets FDA Breakthrough Therapy Designation For Acute Treatment Of Agitation Associated With Dementia   RTTNews
07:01AM EDT  BioXcel Therapeutics Receives FDA Breakthrough Therapy Designation for BXCL501 for the Acute Treatment of Agitation Associated with Dementia   Benzinga
07:00AM EDT  BioXcel Therapeutics Receives FDA Breakthrough Therapy Designation   GlobeNewswire Inc
Mar 11, 2021
08:19AM EST  The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena   Benzinga
07:16AM EST  BioXcel Therapeutics Q4 EPS $(0.87) Beats $(0.96) Estimate   Benzinga
07:15AM EST  BioXcel Submits NDA For BXCL501 For Acute Treatment Of Agitation Associated With Schizophrenia And Bipolar Disorders   RTTNews
07:15AM EST  New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) forBXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation   GlobeNewswire Inc
07:11AM EST  BioXcel Therapeutics Submits New Drug Application to FDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders   Benzinga
07:00AM EST  BioXcel Therapeutics Submits New Drug Application to U.S. Food and   GlobeNewswire Inc
03:35AM EST  Earnings Scheduled For March 11, 2021   Benzinga
Mar 6, 2021
10:58AM EST  The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings   Benzinga
Mar 4, 2021
07:00AM EST  BioXcel Therapeutics to Host Fourth Quarter and Full Year 2020   GlobeNewswire Inc
Mar 3, 2021
09:49AM EST  BioXcel's BXCL501 Lower Dose Shows Statistical Significance On Agitation Scales   Benzinga
07:12AM EST  BioXCel Therapeutics Says Review Of TRANQUILITY Data Showed 30mcg Dose Met 'Statistical Significance Across Multiple Scales;' Co Initiates Supplemental 40mcg Dose Cohort   Benzinga
07:00AM EST  Review of TRANQUILITY data showed 30 mcg dose met statistical significance across multiple scales   GlobeNewswire Inc
Mar 1, 2021
07:00AM EST  BioXcel Therapeutics Appoints June Bray to Board of Directors   GlobeNewswire Inc
Feb 25, 2021
11:46AM EST  BioXcel Therapeutics Starts Testing BXCL501 In Mid-Stage Delirium-Related Agitation Study   Benzinga
07:11AM EST  BioXcel Therapeutics Announces Initiation of Phase 2 PLACIDITY Trial of BXCL501 for the Treatment of Delirium Related Agitation   Benzinga
07:00AM EST  BioXcel Therapeutics Announces Initiation of Phase 2 PLACIDITY   GlobeNewswire Inc
Feb 23, 2021
07:00AM EST  BioXcel Therapeutics Appoints Javier Rodriguez as Chief Legal   GlobeNewswire Inc
Feb 12, 2021
07:00AM EST  BioXcel Therapeutics to Host Virtual Key Opinion Leader Event to   GlobeNewswire Inc
Feb 6, 2021
12:42PM EST  The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight   Benzinga
Feb 4, 2021
07:00AM EST  BioXcel Therapeutics to Present an Update from its Ongoing Trial   GlobeNewswire Inc
Feb 1, 2021
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2021   Benzinga
07:55AM EST  UBS Initiates Coverage On BioXcel Therapeutics with Buy Rating, Announces Price Target of $99   Benzinga
Jan 12, 2021
06:21AM EST  BTAI: Positive Results for BXCL501 in TRANQUILITY Trial; Raising Valuation to $140   Benzinga
Jan 6, 2021
08:19AM EST  10 Biggest Price Target Changes For Wednesday   Benzinga
06:07AM EST  HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Raises Price Target to $185   Benzinga
Jan 5, 2021
10:43AM EST  BioXcel Therapeutics shares were trading higher after the company announced BXCL501 met the primary and all secondary endpoints in the TRANQUILITY Phase 1b/2 study for the acute treatment of agitation in Dementia.   Benzinga
08:39AM EST  The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data   Benzinga
07:17AM EST  BioXcel Therapeutics Announces BXCL501 Met Primary And All Secondary Endpoints In TRANQUILITY Phase 1b/2 Study For Acute Treatment Of Agitation In Dementia, Including Alzheimer's Disease   Benzinga
07:14AM EST  BioXcel Says BXCL501 Meets Endpoints In TRANQUILITY Phase 1b/2 Study For Acute Treatment Of Agitation In Dementia   RTTNews
07:00AM EST  Statistically significant, clinically meaningful, rapid and durable reductions in agitation achieved with the 60 mcg dose as measured by multiple agitation scales   GlobeNewswire Inc
Dec 17, 2020
07:00AM EST  BioXcel Therapeutics to Present at the 39th Annual J.P. Morgan   GlobeNewswire Inc
Dec 7, 2020
07:10AM EST  BioXcel Therapeutics Announces Grant by U.S. Department of Defense to Evaluate BXCL501 in Patients Suffering from PTSD   Benzinga
07:00AM EST  BioXcel Therapeutics Announces Grant by U.S. Department of Defense   GlobeNewswire Inc
Nov 18, 2020
11:03AM EST  Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Raises Price Target to $110   Benzinga
Nov 13, 2020
07:00AM EST  BioXcel Therapeutics, Inc. (BTI or the Company) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference.   GlobeNewswire Inc
Nov 12, 2020
07:16AM EST  BioXcel Therapeutics Q3 EPS $(1.07) Misses $(0.80) Estimate   Benzinga
07:00AM EST  Complete NDA submission forBXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorders on track for Q1 2021   GlobeNewswire Inc
04:18AM EST  Earnings Scheduled For November 12, 2020   Benzinga
Nov 11, 2020
07:17AM EST  BioXcel Therapeutics Completes Pre-NDA Meeting With FDA For BXCL501   RTTNews
07:09AM EST  BioXcel Therapeutics Announces Completion Of Pre-NDA Meeting With FDA For BXCL501 For Acute Treatment Of Agitation In Patients With Schizophrenia And Bipolar Disorders   Benzinga
07:00AM EST  Initiated rolling submission of New Drug Application (NDA) with U.S. Food and Drug Administration (FDA)   GlobeNewswire Inc
Nov 9, 2020
08:09AM EST  BioXcel Therapeutics To Present BXCL701 Clinical Data At Society For Immunotherapy Of Cancer's 35th Anniversary Annual Meeting   Benzinga
08:05AM EST  Encouraging signals of activity in difficult-to-treat tumors observed in both ongoing trials with BXCL701 and pembrolizumab (KEYTRUDA)   GlobeNewswire Inc
Nov 5, 2020
07:00AM EST  BioXcel Therapeutics to Host Third Quarter 2020 Operating and   GlobeNewswire Inc
Oct 26, 2020
07:15AM EDT  BioXcel Therapeutics Gets FDA Clearance Of IND For Phase 2 Trial With BXCL501 For Agitation Associated With Delirium   RTTNews
07:02AM EDT  BioXcel Therapeutics Receives FDA Clearance of IND for Phase 2 Trial with BXCL501 for the Treatment of Agitation Associated with Delirium   Benzinga
07:00AM EDT  BioXcel Therapeutics Receives FDA Clearance of IND for Phase 2   GlobeNewswire Inc
Sep 25, 2020
11:25AM EDT  Cramer Gives His Opinion On BioXcel, Schrodinger And More   Benzinga
Sep 9, 2020
07:00AM EDT  BioXcel Therapeutics, Inc. (BTI or Company) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the H.C. Wainwright 22nd Annual Global Investment Conference.   GlobeNewswire Inc
Sep 2, 2020
10:21AM EDT  Benzinga's Top Upgrades, Downgrades For September 2, 2020   Benzinga
05:21AM EDT  Jefferies Initiates Coverage On BioXcel Therapeutics with Buy Rating, Announces Price Target of $82   Benzinga
Aug 17, 2020
09:31AM EDT  BMO Capital Maintains Outperform on BioXcel Therapeutics, Lowers Price Target to $95   Benzinga
08:26AM EDT  10 Biggest Price Target Changes For Monday   Benzinga
07:19AM EDT  HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $175   Benzinga
Aug 14, 2020
08:26AM EDT  The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal   Benzinga
07:16AM EDT  BioXcel Therapeutics Q2 Net Loss Of $21.4 Mln Opr$1.06/Shr Vs Loss $8.47 Mln Or $0.54/Shr Last Year   RTTNews
07:11AM EDT  BioXcel Therapeutics Q2 EPS $(1.06) Misses $(0.75) Estimate   Benzinga
07:00AM EDT  SERENITY I & II Phase 3 trials of BXCL501 achieved all primary and secondary endpoints; New Drug Application (NDA) submission to U.S. Food and Drug Administration (FDA) planned for Q1 2021   GlobeNewswire Inc
Aug 7, 2020
07:00AM EDT  BioXcel Therapeutics, Inc. (BTI or Company) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Friday, August 14, 2020 at 8:30 AM Eastern Time to discuss its second quarter 2020 operating and financial results.   GlobeNewswire Inc
Aug 6, 2020
07:00AM EDT  BioXcel Therapeutics to Participate in the Canaccord Genuity 40th   GlobeNewswire Inc
Jul 29, 2020
05:29AM EDT  BioXcel Therapeutics Prices 4M Share Public Offering of Common Stock @$50/Share   Benzinga
Jul 27, 2020
04:22PM EDT  BioXcel Therapeutics Announces Proposed $200M Public Offering Of Common Stock   Benzinga
04:21PM EDT  BioXcel Therapeutics Announces Proposed Public Offering of Common   GlobeNewswire Inc
04:12PM EDT  BioXcel Therapeutics Files For Mixed Shelf Offering By Selling Shareholders; Size Not Disclosed   Benzinga
Jul 20, 2020
09:56AM EDT  Shares of BioXcel Therapeutics, Inc. (BTAI) are currently up nearly 30% on Monday morning trade after the company said that two late-stage trials of treatment for schizophrenia and bipolar disorder met their primary endpoints.   RTTNews
07:49AM EDT  HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Raises Price Target to $200   Benzinga
07:43AM EDT  Benzinga Pro's Top 5 Stocks To Watch: SNAP, TSLA, JAZZ, BTAI, SBUX   Benzinga
07:12AM EDT  BioXcel Therapeutics Announces Primary And Secondary Endpoints Met In Two SERENITY Trials   RTTNews
07:07AM EDT  BioXcel Therapeutics Announces Primary And Secondary Endpoints Met In Two Pivotal Phase 3 Trials Of BXCL501 For Acute Treatment Of Agitation In Patients With Schizophrenia And Bipolar Disorder   Benzinga
07:00AM EDT  Highly statistically significant improvements in PEC score observed vs. placebo (p<0.0001) at two hours in the SERENITY trials for both doses tested   GlobeNewswire Inc
Jul 13, 2020
07:52AM EDT  B of A Securities Reiterates Buy on BioXcel Therapeutics, Raises Price Target to $63   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC